Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 10
  • previous
  • 1
  • next
Item hits:
Issue DateTitleAuthor(s)
11-Dec-2018FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through Thymidylate synthase (TYMS) : implications of FOXM1-TYMS axis uncoupling in 5-FU resistanceIntuyod, K; Saavedra Garcia, P; Zona, S; Lai, CF; Jiramongkol, Y, et al
4-Dec-2017CryoEM structures of the human INO80 chromatin remodelling complexZhang, X; Aramayo, RJ; Willhoft, O; Ayala, R; Bythell-Douglas, R, et al
10-Feb-2016miR-515-5p controls cancer cell migration through MARK4 regulationPardo, OE; Munro, CE; Castellano, L; Hu, Y; Mauri, F, et al
10-May-2018TGF-ß induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progressionOttaviani, S; Stebbing, J; Frampton, A; Zagorac, S; Krell, J, et al
26-May-2017De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trialClark, RE; Polydoros, F; Apperley, JF; Milojkovic, D; Pocock, C, et al
15-Aug-2016RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatmentLam, EW; Kongsema, M; Zona, S; Karunarathna, U; Yao, S, et al
13-Mar-2018SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cellsNestal de Moraes, G; Ji, Z; Lavender, F; Yao, S; Zona, S, et al
4-Apr-2016BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancerLam, EW; Gong, C; Yao, S; Gomes, AR; Cancer Research UK, et al
1-Jun-2018The FOXO3-FOXM1 Axis: a key cancer drug target and a modulator of cancer drug resistanceYao, S; Fan, YN; Lam, EW; Biotechnology and Biological Sciences Research Council (BBSRC); Imperial College Trust, et al
30-Nov-2018The argument for using imatinib in CMLClaudiani, S; Apperley, JF; Imperial College Trust; Novartis Pharmaceuticals UK Limited; Leuka, et al